


**SCARD Pool report for 01-01-2006 to 31-12-2006**

|                     |                             |     |         |
|---------------------|-----------------------------|-----|---------|
| <b>Participants</b> | Doctors                     | 17  |         |
|                     | Patients                    | 471 |         |
| <b>Specimens</b>    | New lesions                 | 673 | 83.81%  |
|                     | Previously biopsied lesions | 130 | 16.19%  |
|                     | Total lesions               | 803 | 100.00% |

**Breakdown of new versus previously biopsied specimens**


|  |        |
|--|--------|
| Percentage of new lesions tested which were malignant          | 44.24% |
| Percentage of Definitively excised lesions that were malignant | 52.15% |
| Lesions tested to find one melanoma (NNT)                      | 22.63  |
| Percentage of lesions tested for NMSC which were NMSC          | 60.51% |
| Ratio of New BCCs : New Melanomas                              | 19:1   |

**Accuracy**
**Diagnostic sensitivity**

|           |               |
|-----------|---------------|
| Melanomas | 62.50% of 8   |
| All NMSC  | 95.09% of 285 |
| BCCs      | 94.19% of 155 |
| SCCs      | 66.41% of 128 |

**Positive predictive value**


|           |               |
|-----------|---------------|
| Melanomas | 25.00% of 20  |
| All NMSC  | 78.55% of 345 |
| BCCs      | 42.32% of 345 |
| SCCs      | 68.00% of 125 |

**Adequacy**
**Percentage of definitively managed malignant cases where surgical margins were adequate**

|                           |               |
|---------------------------|---------------|
| BCC                       | 94.39% of 107 |
| IEC/Bowens disease        | 100.00% of 23 |
| SCC                       | 91.84% of 49  |
| Keratoacanthoma           | 100.00% of 3  |
| Melanoma - in situ        | 100.00% of 6  |
| Melanoma - invasive       | 75.00% of 4   |
| Melanoma - invasive > 1mm | 0% of 0       |
| Other malignant           | 100.00% of 1  |

**Lesion Breakdown**  
**Histological Diagnosis**

|                             |    |        |
|-----------------------------|----|--------|
| BCC (unspecified type)      | 75 | 11.05% |
| BCC - Superficial           | 31 | 4.57%  |
| BCC - Nodular/Solid         | 35 | 5.15%  |
| BCC - Aggressive            | 14 | 2.06%  |
| IEC/Bowens disease          | 41 | 6.04%  |
| SCC                         | 84 | 12.37% |
| Keratoacanthoma             | 3  | 0.44%  |
| Pinkus Fibroepithelioma     | 0  | 0%     |
| Merkel cell tumour          | 0  | 0%     |
| Other malignant             | 1  | 0.15%  |
| NMSC Metastasis             | 0  | 0%     |
| Melanoma - in situ          | 6  | 0.88%  |
| Melanoma - invasive         | 2  | 0.29%  |
| Melanoma - invasive > 1mm   | 0  | 0%     |
| Melanoma - metastasis       | 0  | 0%     |
| MELTUMP                     | 1  | 0.15%  |
| Naevus - other              | 83 | 12.22% |
| Naevus - dysplastic/Clark   | 38 | 5.60%  |
| Naevus - blue               | 2  | 0.29%  |
| Naevus - Spitz/Reed         | 2  | 0.29%  |
| Naevus - Compound           | 0  | 0%     |
| Solar keratosis             | 47 | 6.92%  |
| Solar lentigo               | 9  | 1.33%  |
| Seborrhoeic keratosis       | 69 | 10.16% |
| Lentigo Simplex             | 0  | 0%     |
| Lichenoid keratosis (LPLK)  | 4  | 0.59%  |
| Dermatofibroma              | 8  | 1.18%  |
| Sebaceous gland hyperplasia | 2  | 0.29%  |
| Benign cyst                 | 14 | 2.06%  |
| Other benign                | 89 | 13.11% |
| Histology Pending           | 6  | 0.88%  |



**Procedures**
**Definitive Surgical Management used to exclude melanoma**

|                       |    |        |
|-----------------------|----|--------|
| Ellipse               | 89 | 94.68% |
| Flap                  | 0  | 0%     |
| Graft - SSG           | 0  | 0%     |
| Graft - FTSG          | 0  | 0%     |
| No Closure            | 4  | 4.26%  |
| Shave/Saucerisation   | 0  | 0%     |
| Curettage & Cautery   | 1  | 1.06%  |
| Liquid N2 freeze/thaw | 0  | 0%     |
| PDT                   | 0  | 0%     |
| Imiquimod             | 0  | 0%     |
| 5 FU cream            | 0  | 0%     |
| GP referral           | 0  | 0%     |
| Specialist referral   | 0  | 0%     |
| Other                 | 0  | 0%     |

**Biopsy used to exclude melanoma**

|                 |    |        |
|-----------------|----|--------|
| Punch - sample  | 10 | 11.49% |
| Shave - sample  | 12 | 13.79% |
| Incisional      | 1  | 1.15%  |
| Punch - removal | 5  | 5.75%  |
| Shave - removal | 6  | 6.90%  |
| Excisional      | 53 | 60.92% |
| Curettage       | 0  | 0%     |
| Other           | 0  | 0%     |

**Breakdown of definitive management procedures for malignant conditions**

|                       |     |        |
|-----------------------|-----|--------|
| Ellipse               | 206 | 67.10% |
| Flap                  | 11  | 3.58%  |
| Graft - SSG           | 0   | 0%     |
| Graft - FTSG          | 1   | 0.33%  |
| No Closure            | 0   | 0%     |
| Shave/Saucerisation   | 0   | 0%     |
| Curettage & Cautery   | 11  | 3.58%  |
| Liquid N2 freeze/thaw | 4   | 1.30%  |
| PDT                   | 1   | 0.33%  |
| Imiquimod             | 17  | 5.54%  |
| 5 FU cream            | 0   | 0%     |
| GP referral           | 1   | 0.33%  |
| Specialist referral   | 54  | 17.59% |
| Other                 | 0   | 0%     |

**Breakdown of definitive management procedures for benign conditions**

|                       |     |        |
|-----------------------|-----|--------|
| Ellipse               | 130 | 78.31% |
| Flap                  | 0   | 0%     |
| Graft - SSG           | 0   | 0%     |
| Graft - FTSG          | 0   | 0%     |
| No Closure            | 6   | 3.61%  |
| Shave/Saucerisation   | 0   | 0%     |
| Liquid N2 freeze/thaw | 6   | 3.61%  |
| 5 FU cream            | 6   | 3.61%  |
| GP referral           | 0   | 0%     |
| Specialist referral   | 1   | 0.60%  |
| Other                 | 0   | 0%     |

**Procedures (continued)**
**Percentage of procedures/closures that were complex**

|  |           |
|--|-----------|
| Complex Closures                           | 0% of 207 |
| Complex Closures (inc Curettage & Cautery) | 0% of 224 |

**Locations**
**Breakdown of melanomas by location and percentage melanomas of total lesions at that location**

|               |   |              |
|---------------|---|--------------|
| Nose          | 0 | 0% of 31     |
| Lip           | 0 | 0% of 14     |
| Ear           | 0 | 0% of 20     |
| Eyelid        | 0 | 0% of 3      |
| Other face    | 0 | 0% of 53     |
| Scalp         | 0 | 0% of 15     |
| Neck          | 1 | 2.94% of 34  |
| Shoulder      | 2 | 5.88% of 34  |
| Chest         | 0 | 0% of 46     |
| Abdomen       | 0 | 0% of 18     |
| Genitalia     | 0 | 0% of 0      |
| Back          | 2 | 1.82% of 110 |
| Buttock       | 1 | 11.11% of 9  |
| Arm           | 0 | 0% of 30     |
| Forearm       | 0 | 0% of 41     |
| Hand Dorsal   | 0 | 0% of 37     |
| Hand Palmar   | 0 | 0% of 0      |
| Finger Dorsal | 0 | 0% of 7      |
| Finger Nail   | 0 | 0% of 0      |
| Finger Palmar | 0 | 0% of 1      |
| Thigh         | 2 | 6.25% of 32  |
| Leg           | 0 | 0% of 68     |
| Foot Dorsal   | 0 | 0% of 10     |
| Foot Plantar  | 0 | 0% of 8      |
| Toe Dorsal    | 0 | 0% of 3      |
| Toe Nail      | 0 | 0% of 0      |
| Toe Plantar   | 0 | 0% of 0      |
| Palm Or Sole  | 0 | 0% of 0      |

